Changeflow GovPing Healthcare & Life Sciences Patent Application for Benzofuran Derivatives a...
Routine Notice Added Draft

Patent Application for Benzofuran Derivatives as SIK Inhibitors

Email

Summary

The USPTO has published a patent application (US20260085053A1) from BEONE MEDICINES I GMBH for benzofuran derivatives that act as SIK inhibitors. These compounds are intended for the treatment of various inflammatory diseases.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application detailing novel benzofuran derivatives designed as salt-inducible kinase (SIK) inhibitors. The application, filed by BEONE MEDICINES I GMBH, includes specific compound structures (formula I) and outlines their potential use in treating inflammatory diseases. The application number is 19405502, and it was filed on December 2, 2025.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future developments in pharmaceutical research and development for inflammatory conditions. Companies operating in the pharmaceutical sector, particularly those involved in drug discovery and development for inflammatory diseases, should be aware of this filing as it may impact future intellectual property landscapes and competitive research efforts.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF

Application US20260085053A1 Kind: A1 Mar 26, 2026

Assignee

BEONE MEDICINES I GMBH

Inventors

Jing Li, Fengtao Song, Zhiwei Wang

Abstract

Provided are compounds of formula (I) as well as their compositions and methods of use, wherein values for variables R1, R2, R5, X, X1, and X2 are provided herein. The compounds inhibit salt-inducible kinase activity and are useful in the treatment of various inflammatory diseases.

CPC Classifications

C07D 307/83 A61K 31/343 A61K 31/351 A61K 31/397 A61K 31/4025 A61K 31/403 A61K 31/4035 A61K 31/404 A61K 31/4155 A61K 31/4178 A61K 31/422 A61K 31/4245 A61K 31/438 A61K 31/443 A61K 31/4525 A61K 31/454 A61K 31/4709 A61K 31/4725 A61K 31/496 A61K 31/501 A61K 31/506 A61K 31/5377 A61K 31/538 A61K 31/553 C07D 405/04 C07D 405/12 C07D 405/14 C07D 407/12 C07D 413/12 C07D 413/14 C07D 471/10 C07D 491/048

Filing Date

2025-12-02

Application No.

19405502

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260085053A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Development Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!